patent/WO-9938504-A8

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9938504-A8

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
filingDate	1999-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ca36d47a11e747fc370dd1e4126f914
publicationDate	2000-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	WO-9938504-A8
titleOfInvention	Pharmaceutical uses of optically pure (-)-bupropion
abstract	Methods and compositions are disclosed utilizing the optically pure (-)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain, bipolar disorders, attention-deficit disorders, conduct disorders, phycho-sexual dysfunction, bulimia, eating disorders or specific food craving. The composition can be administered intravenously, transdermally (patch) or orally, possibily in a sustained release form.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248123-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8916195-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9457005-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9125868-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9107837-B2
priorityDate	1998-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226424248 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419532742

Total number of triples: 39.